Einzeltreffer — DigiBib

Inflammatory responses, especially chronic inflammation, are closely associated with many systemic diseases. There are many ways to treat and alleviate inflammation, but how to solve this problem at the molecular level has always been a hot topic in research. The use of nanoparticles (NPs) as anti-inflammatory agents is a potential treatment method. We synthesized new hollow cerium oxide nanomaterials ( h CeO 2 NPs) doped with different concentrations of Cu 5.4 O NPs [the molar ratio of Cu/(Ce + Cu) was 50%, 67%, and 83%, respectively], characterized their surface morphology and physicochemical properties, and screened the safe concentration of h CeO 2 @Cu 5.4 O using the CCK8 method. Macrophages were cultured, and P.g -lipopolysaccharide-stimulated was used as a model of inflammation and co-cultured with h CeO 2 @Cu 5.4 O NPs. We then observe the effect of the transcription levels of CTSB, NLRP3, caspase-1, ASC, IL-18, and IL-1β by PCR and detect its effect on the expression level of CTSB protein by Western blot. The levels of IL-18 and IL-1β in the cell supernatant were measured by enzyme-linked immunosorbent assay. Our results indicated that h CeO 2 @Cu 5.4 O NPs could reduce the production of reactive oxygen species and inhibit CTSB and NLRP3 to alleviate the damage caused by the inflammatory response to cells. More importantly, h CeO 2 @Cu 5.4 O NPs showed stronger anti-inflammatory effects as Cu 5.4 O NP doping increased. Therefore, the development of the novel nanomaterial h CeO 2 @Cu 5.4 O NPs provides a possible new approach for the treatment of inflammatory diseases.

Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Titel:	<subscript>h</subscript> CeO <subscript>2</subscript> @ Cu <subscript>5.4</subscript> O nanoparticle alleviates inflammatory responses by regulating the CTSB-NLRP3 signaling pathway.
Autor/in / Beteiligte Person:	Li, Y ; Xia, X ; Niu, Z ; Wang, K ; Liu, J ; Li, X
Link:	Full Text Finder (Volltext)
Zeitschrift:	Frontiers in immunology, Jg. 15 (2024-04-22), S. 1344098
Veröffentlichung:	[Lausanne : Frontiers Research Foundation], 2024
Medientyp:	academicJournal
ISSN:	1664-3224 (electronic)
DOI:	10.3389/fimmu.2024.1344098
Schlagwort:	Animals Mice Nanoparticles Macrophages drug effects Macrophages immunology Macrophages metabolism Inflammasomes metabolism Inflammasomes drug effects RAW 264.7 Cells Reactive Oxygen Species metabolism NLR Family, Pyrin Domain-Containing 3 Protein metabolism Cerium pharmacology Cerium chemistry Signal Transduction drug effects Inflammation drug therapy Inflammation metabolism Copper Anti-Inflammatory Agents pharmacology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Front Immunol] 2024 Apr 22; Vol. 15, pp. 1344098. <i>Date of Electronic Publication: </i>2024 Apr 22 (<i>Print Publication: </i>2024). MeSH Terms: NLR Family, Pyrin Domain-Containing 3 Protein* / metabolism ; Cerium* / pharmacology ; Cerium* / chemistry ; Signal Transduction* / drug effects ; Inflammation* / drug therapy ; Inflammation* / metabolism ; Copper* ; Anti-Inflammatory Agents* / pharmacology ; Animals ; Mice ; Nanoparticles ; Macrophages / drug effects ; Macrophages / immunology ; Macrophages / metabolism ; Inflammasomes / metabolism ; Inflammasomes / drug effects ; RAW 264.7 Cells ; Reactive Oxygen Species / metabolism References: J Mater Chem B. 2021 Sep 15;9(35):7238-7245. (PMID: 34095923) ; PLoS One. 2013;8(1):e55375. (PMID: 23383169) ; Inflamm Res. 2006 Sep;55(9):359-63. (PMID: 17122956) ; PLoS Pathog. 2018 Jan 23;14(1):e1006872. (PMID: 29360865) ; J Physiol Biochem. 2018 Nov;74(4):503-510. (PMID: 30019185) ; Nanoscale. 2011 Apr;3(4):1411-20. (PMID: 21369578) ; Toxicol Sci. 2014 Dec;142(2):497-507. (PMID: 25260831) ; Cell Death Dis. 2011 Oct 06;2:e213. (PMID: 21975295) ; Adv Wound Care (New Rochelle). 2023 Sep;12(9):529-543. (PMID: 36680757) ; Environ Res. 2023 Aug 15;231(Pt 1):115983. (PMID: 37137456) ; Biochem Biophys Res Commun. 2012 Aug 24;425(2):121-6. (PMID: 22796220) ; Anal Bioanal Chem. 2021 Jan;413(3):839-851. (PMID: 33219832) ; Biomed Pharmacother. 2019 Jan;109:2561-2572. (PMID: 30551516) ; Carbohydr Polym. 2023 Jul 1;311:120718. (PMID: 37028867) ; Int J Nanomedicine. 2013;8:4507-20. (PMID: 24294000) ; Cell Res. 2011 Jan;21(1):103-15. (PMID: 21187859) ; Hamostaseologie. 2015;35(2):99, 101. (PMID: 25943077) ; Int J Nanomedicine. 2021 Mar 01;16:1709-1724. (PMID: 33688187) ; FEMS Immunol Med Microbiol. 2007 Dec;51(3):443-52. (PMID: 17903207) ; Bioact Mater. 2021 Mar 09;6(10):3109-3124. (PMID: 33778192) ; Cell Prolif. 2021 Feb;54(2):e12973. (PMID: 33382502) ; Nanoscale. 2022 Feb 17;14(7):2628-2637. (PMID: 35088792) ; Int J Nanomedicine. 2022 Dec 21;17:6561-6578. (PMID: 36578441) ; Adv Healthc Mater. 2019 Aug;8(16):e1900256. (PMID: 31290270) ; Trends Biochem Sci. 2016 Dec;41(12):1012-1021. (PMID: 27669650) ; ACS Nano. 2019 Mar 26;13(3):3206-3217. (PMID: 30830763) ; Nat Rev Microbiol. 2009 Feb;7(2):99-109. (PMID: 19148178) ; Autophagy. 2016 Dec;12(12):2504-2505. (PMID: 27786577) ; Int J Mol Med. 2014 Jul;34(1):341-9. (PMID: 24789624) ; J Clin Invest. 2009 Feb;119(2):305-14. (PMID: 19164858) ; Int J Toxicol. 2020 Sep/Oct;39(5):397-421. (PMID: 32672081) ; Front Immunol. 2013 Nov 22;4:398. (PMID: 24319446) ; Cancers (Basel). 2019 Nov 26;11(12):. (PMID: 31779223) ; Nat Commun. 2020 Jun 3;11(1):2788. (PMID: 32493916) ; Clin Exp Immunol. 2006 Oct;146(1):169-80. (PMID: 16968411) ; Part Fibre Toxicol. 2012 May 09;9:14. (PMID: 22571318) ; Int J Biochem Cell Biol. 2016 Dec;81(Pt B):281-293. (PMID: 27373679) ; Cell. 2010 Mar 19;140(6):871-82. (PMID: 20303877) ; Nature. 2010 Apr 29;464(7293):1357-61. (PMID: 20428172) ; J Nanobiotechnology. 2022 Mar 4;20(1):107. (PMID: 35246140) ; Biol Chem. 2016 Dec 21;398(3):289-301. (PMID: 28002019) ; Eur Cell Mater. 2012 Sep 24;24:249-65. (PMID: 23007910) ; Nat Rev Immunol. 2019 Aug;19(8):477-489. (PMID: 31036962) ; Molecules. 2020 Oct 06;25(19):. (PMID: 33036163) ; J Mater Chem B. 2016 May 21;4(19):3195-3202. (PMID: 32263255) ; Nanotoxicology. 2015 May;9 Suppl 1:13-24. (PMID: 23889211) ; J Immunol. 2008 Jun 1;180(11):7147-57. (PMID: 18490713) ; Mol Ther Nucleic Acids. 2022 Sep 23;30:198-207. (PMID: 36250207) ; Cell Physiol Biochem. 2017;44(6):2189-2200. (PMID: 29298445) ; Nat Rev Immunol. 2010 Dec;10(12):826-37. (PMID: 21088683) ; PLoS One. 2014 Aug 07;9(8):e104498. (PMID: 25101660) ; Inflammation. 2017 Dec;40(6):1933-1943. (PMID: 28766178) ; Bioact Mater. 2023 Jan 26;25:95-106. (PMID: 36789001) ; J Neurosci. 2015 Sep 9;35(36):12488-501. (PMID: 26354916) ; Int Immunopharmacol. 2021 May;94:107496. (PMID: 33639565) ; Ann Afr Med. 2019 Jul-Sep;18(3):121-126. (PMID: 31417011) ; J Hazard Mater. 2012 Jan 30;201-202:244-9. (PMID: 22178277) ; Diabetes Obes Metab. 2011 Apr;13(4):289-301. (PMID: 21205111) ; Free Radic Res. 2021 Apr;55(4):331-342. (PMID: 33336617) ; Colloids Surf B Biointerfaces. 2022 Dec;220:112960. (PMID: 36308885) ; Int J Mol Sci. 2019 Jul 06;20(13):. (PMID: 31284572) ; J Biomed Mater Res A. 2014 Jun;102(6):1838-49. (PMID: 23784947) ; Int J Nanomedicine. 2022 Jan 29;17:477-494. (PMID: 35125869) ; Inflamm Res. 2015 Oct;64(10):799-808. (PMID: 26298161) Contributed Indexing: Keywords: CTSB; NLRP3; anti-inflammation; cerium oxide nanoparticles; copper-based nanoparticles Substance Nomenclature: 0 (NLR Family, Pyrin Domain-Containing 3 Protein) ; 30K4522N6T (Cerium) ; 789U1901C5 (Copper) ; 619G5K328Y (ceric oxide) ; 0 (Anti-Inflammatory Agents) ; 0 (Nlrp3 protein, mouse) ; 0 (Inflammasomes) ; 0 (Reactive Oxygen Species) Entry Date(s): Date Created: 20240507 Date Completed: 20240507 Latest Revision: 20240529 Update Code: 20240529 PubMed Central ID: PMC11070469

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

<subscript>h</subscript> CeO <subscript>2</subscript> @ Cu <subscript>5.4</subscript> O nanoparticle alleviates inflammatory responses by regulating the CTSB-NLRP3 signaling pathway.